
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5443037/publications.pdf Version: 2024-02-01



SUJUN ZHENC

#	Article	IF	CITATIONS
1	Stem Cells Treatment for Wilson Disease. Current Stem Cell Research and Therapy, 2022, 17, 712-719.	0.6	3
2	Prediction of biochemical nonresolution in patients with chronic drugâ€induced liver injury: A large multicenter study. Hepatology, 2022, 75, 1373-1385.	3.6	17
3	Direct-acting Antiviral-induced Transient Recovery of NK Cells in Early-stage Treatment of Chronic Hepatitis C Patients. Journal of Clinical and Translational Hepatology, 2022, 000, 000-000.	0.7	2
4	Respiratory failure as the prominent manifestation of entecavir-associated mitochondrial myopathy: a case report. BMC Infectious Diseases, 2022, 22, 188.	1.3	3
5	Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues. Journal of Viral Hepatitis, 2022, 29, 420-431.	1.0	6
6	A standardized assay for the quantitative detection of serum HBV RNA in chronic hepatitis B patients. Emerging Microbes and Infections, 2022, 11, 775-785.	3.0	7
7	Comparison of the Effectiveness and Safety of d-Penicillamine and Zinc Salt Treatment for Symptomatic Wilson Disease: A Systematic Review and Metaâ€Analysis. Frontiers in Pharmacology, 2022, 13, 847436.	1.6	8
8	A Novel Mutation of Transferrin Receptor 2 in a Chinese Pedigree With Type 3 Hemochromatosis: A Case Report. Frontiers in Genetics, 2022, 13, 836431.	1.1	0
9	Clinical Features and T Cell Immune Characteristics of Postpartum Hepatitis Flare in Pregnant Women With HBeAg-Positive Chronic HBV Infection. Frontiers in Immunology, 2022, 13, 881321.	2.2	5
10	M2-like macrophages exert hepatoprotection in acute-on-chronic liver failure through inhibiting necroptosis-S100A9-necroinflammation axis. Cell Death and Disease, 2021, 12, 93.	2.7	40
11	Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: A singleâ€arm, open″abel, phase 3 trial. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2375-2382.	1.4	3
12	Prevalence and clinical correlates of insomnia symptoms and their association with quality of life in Chinese patients with HBV-related liver disease. PeerJ, 2021, 9, e10956.	0.9	2
13	UGT1A1-related Bilirubin Encephalopathy/Kernicterus in Adults. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	0.7	2
14	A novel compound heterozygous mutation in ABCB4 gene in a pedigree with progressive familial intrahepatic cholestasis 3: a case report. Annals of Translational Medicine, 2021, 9, 426-426.	0.7	4
15	HBeAg-positive patients with HBsAg  < 100ÂlU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation. Journal of Gastroenterology, 2021, 56, 856-867.	 2.3	18
16	Clinical and Immunological Factors Associated with Postpartum Hepatic Flares in Immune-Tolerant Pregnant Women with Hepatitis B Virus Infection Treated with Telbivudine. Gut and Liver, 2021, 15, 887-894.	1.4	6
17	Cost-effectiveness of combination antiviral treatment with extended duration for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B in China. Annals of Translational Medicine, 2021, 9, 1365-1365.	0.7	3
18	Serum Anti-14-3-3 Zeta Autoantibody as a Biomarker for Predicting Hepatocarcinogenesis. Frontiers in Oncology, 2021, 11, 733680.	1.3	3

#	Article	IF	CITATIONS
19	Pegylated Interferon Treatment for the Effective Clearance of Hepatitis B Surface Antigen in Inactive HBsAg Carriers: A Meta-Analysis. Frontiers in Immunology, 2021, 12, 779347.	2.2	11
20	Association of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis. BMC Gastroenterology, 2021, 21, 490.	0.8	4
21	Upregulation of Serum Sphingosine (d18:1)-1-P Potentially Contributes to Distinguish HCC Including AFP-Negative HCC From Cirrhosis. Frontiers in Oncology, 2020, 10, 1759.	1.3	9
22	Risk factors related to postpartum hepatic inflammation in pregnant women with chronic hepatitis B. Journal of International Medical Research, 2020, 48, 030006052096643.	0.4	4
23	Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A singleâ€arm, openâ€label, phase 3 trial. Liver International, 2020, 40, 2685-2693.	1.9	9
24	Efficacy and Safety of All-oral Emitasvir and Sofosbuvir in Patients with Genotype 1b HCV Infections without Cirrhosis. Journal of Clinical and Translational Hepatology, 2020, 8, 1-7.	0.7	2
25	Platelet count is closely associated with the severity of liver injury in patients with chronic hepatitis B virus infection: A cross‑sectional study. Experimental and Therapeutic Medicine, 2020, 20, 243-250.	0.8	2
26	Exploring the Diagnostic Potential of Serum Golgi Protein 73 for Hepatic Necroinflammation and Fibrosis in Chronic HCV Infection with Different Stages of Liver Injuries. Disease Markers, 2019, 2019, 1-10.	0.6	10
27	Stevens–Johnson syndrome and acute vanishing bile duct syndrome after the use of amoxicillin and naproxen in a child. Journal of International Medical Research, 2019, 47, 4537-4543.	0.4	14
28	Complex <i>ATP7B</i> mutation patterns in Wilson disease and evaluation of a yeast model for functional analysis of variants. Human Mutation, 2019, 40, 552-565.	1.1	16
29	Letter to the Editor: Suggestions for Rational Management of Nonalcoholic Fatty Liver Disease. Hepatology, 2019, 70, 1492-1493.	3.6	0
30	Efficacy of antepartum administration of hepatitis B immunoglobulin in preventing motherâ€ŧo hild transmission of hepatitis B virus. Journal of Viral Hepatitis, 2019, 26, 1059-1065.	1.0	7
31	Cover Image, Volume 40, Issue 5. Human Mutation, 2019, 40, i-i.	1.1	0
32	Novel mutations found in the ATP7B gene in Chinese patients with Wilson's disease. Molecular Genetics & Genomic Medicine, 2019, 7, e649.	0.6	3
33	Phenotypic switch of human and mouse macrophages and resultant effects on apoptosis resistance in hepatocytes. Innate Immunity, 2019, 25, 176-185.	1.1	7
34	Combined Effects of UGT1A1 and SLCO1B1 Variants on Chinese Adult Mild Unconjugated Hyperbilirubinemia. Frontiers in Genetics, 2019, 10, 1073.	1.1	8
35	Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naĀ ⁻ ve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China. Journal of Clinical and Translational Hepatology, 2019, 7, 1-8.	0.7	12
36	Cellular Mechanisms of Hepatoprotection Mediated by M2-Like Macrophages. Medical Science Monitor, 2018, 24, 2675-2682.	0.5	9

#	Article	IF	CITATIONS
37	Genetically Regulated Bilirubin and Risk of Non-alcoholic Fatty Liver Disease: A Mendelian Randomization Study. Frontiers in Genetics, 2018, 9, 662.	1.1	16
38	Mutation analysis of the ABCC2 gene in Chinese patients with Dubin‑Johnson syndrome. Experimental and Therapeutic Medicine, 2018, 16, 4201-4206.	0.8	11
39	Non- <i>HFE</i> mutations in haemochromatosis in China: combination of heterozygous mutations involving <i>HJV</i> signal peptide variants. Journal of Medical Genetics, 2018, 55, 650-660.	1.5	21
40	Cathepsin H–Mediated Degradation of HDAC4 for Matrix Metalloproteinase Expression in Hepatic Stellate Cells. American Journal of Pathology, 2017, 187, 781-797.	1.9	23
41	Prevalence of Major Depression and Its Associations With Demographic and Clinical Characteristics and Quality of Life in Chinese Patients With HBV-related Liver Diseases. Archives of Psychiatric Nursing, 2017, 31, 287-290.	0.7	5
42	Cationic Polystyrene Resolves Nonalcoholic Steatohepatitis, Obesity, and Metabolic Disorders by Promoting Eubiosis of Gut Microbiota and Decreasing Endotoxemia. Diabetes, 2017, 66, 2137-2143.	0.3	24
43	Efficient inhibition of duck hepatitis B virus DNA by the CRISPR/Cas9 system. Molecular Medicine Reports, 2017, 16, 7199-7204.	1.1	15
44	Glucosylceramide synthase regulates the proliferation and apoptosis of liver cells in vitro by Bcl-2/Bax pathway. Molecular Medicine Reports, 2017, 16, 7355-7360.	1.1	16
45	Current treatment status and barriers for patients with chronic HCV infection in mainland China. Medicine (United States), 2017, 96, e7885.	0.4	18
46	M2-like macrophages in the fibrotic liver protect mice against lethal insults through conferring apoptosis resistance to hepatocytes. Scientific Reports, 2017, 7, 10518.	1.6	46
47	Immune Regulation of Intrahepatic Regulatory T Cells in Fibrotic Livers of Mice. Medical Science Monitor, 2017, 23, 1009-1016.	0.5	15
48	The Psychometric Properties of the Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR) in Patients with HBV-Related Liver Disease. Shanghai Archives of Psychiatry, 2017, 29, 15-20.	0.7	2
49	Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy. Experimental and Therapeutic Medicine, 2016, 11, 117-123.	0.8	2
50	Peroxisome proliferator-activated receptor alpha acts as a mediator of endoplasmic reticulum stress-induced hepatocyte apoptosis in acute liver failure. DMM Disease Models and Mechanisms, 2016, 9, 799-809.	1.2	19
51	Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B. Experimental and Therapeutic Medicine, 2016, 11, 2293-2299.	0.8	4
52	Coverage of different health insurance programs and medical costs associated with chronic hepatitis C infection in mainland China: a cross-sectional survey in 20 provinces. Hepatology, Medicine and Policy, 2016, 1, 7.	1.7	3
53	Inhibition of the translocation and extracellular release of high-mobility group box 1 alleviates liver damage in fibrotic mice in response to D-galactosamine/lipopolysaccharide challenge. Molecular Medicine Reports, 2016, 13, 3835-3841.	1.1	15
54	Persistence of cirrhosis is maintained by intrahepatic regulatory T cells that inhibit fibrosis resolution by regulating the balance of tissue inhibitors of metalloproteinases and matrix metalloproteinases. Translational Research, 2016, 169, 67-79.e2.	2.2	28

#	Article	IF	CITATIONS
55	Plasma sphingolipids: Potential biomarkers for severe hepatic fibrosis in chronic hepatitis C. Molecular Medicine Reports, 2015, 12, 323-330.	1.1	18
56	Increased glyceraldehyde-3-phosphate dehydrogenase expression indicates higher survival rates in male patients with hepatitisÂB virus-accociated hepatocellular carcinoma and cirrhosis. Experimental and Therapeutic Medicine, 2015, 9, 1597-1604.	0.8	2
57	Delayed Reduction of Hepatitis B Viral Load and Dynamics of Adefovir-Resistant Variants during Adefovir plus Entecavir Combination Rescue Therapy. International Journal of Medical Sciences, 2015, 12, 416-422.	1.1	4
58	Hepatitis B Virus X Protein Stabilizes Cyclin D1 and Increases Cyclin D1 Nuclear Accumulation through ERK-Mediated Inactivation of GSK-3β. Cancer Prevention Research, 2015, 8, 455-463.	0.7	20
59	Serum sphingomyelin has potential to reflect hepatic injury in chronic hepatitis B virus infection. International Journal of Infectious Diseases, 2015, 33, 149-155.	1.5	21
60	Changes in Mitochondrial Toxicity in Peripheral Blood Mononuclear Cells During Four-Year Administration of Entecavir Monotherapy in Chinese Patients with Chronic Hepatitis B. Medical Science Monitor, 2015, 21, 2058-2063.	0.5	3
61	Serum vitamin D ₃ does not correlate with liver fibrosis in chronic hepatitis C. World Journal of Gastroenterology, 2015, 21, 11152.	1.4	10
62	Changing Interdigestive Migrating Motor Complex in Rats under Acute Liver Injury. BioMed Research International, 2014, 2014, 1-7.	0.9	1
63	Vitamin D deficiency promotes nonalcoholic steatohepatitis through impaired enterohepatic circulation in animal model. American Journal of Physiology - Renal Physiology, 2014, 307, G883-G893.	1.6	50
64	Fibrosis progression in interferon treatment-naive Chinese plasma donors with chronic hepatitis C for 20 years: a cohort study. International Journal of Infectious Diseases, 2014, 27, 49-53.	1.5	14
65	Inhibition of 5-Lipoxygenase Pathway Attenuates Acute Liver Failure by Inhibiting Macrophage Activation. Journal of Immunology Research, 2014, 2014, 1-9.	0.9	15
66	Autoantibody Response to Murine Double Minute 2 Protein in Immunodiagnosis of Hepatocellular Carcinoma. Journal of Immunology Research, 2014, 2014, 1-10.	0.9	8
67	Plasma Sphingolipids as Potential Indicators of Hepatic Necroinflammation in Patients with Chronic Hepatitis C and Normal Alanine Aminotransferase Level. PLoS ONE, 2014, 9, e95095.	1.1	16
68	Serum Sphingolipids Reflect the Severity of Chronic HBV Infection and Predict the Mortality of HBV-Acute-on-Chronic Liver Failure. PLoS ONE, 2014, 9, e104988.	1.1	18
69	Prognostic value of M30/M65 for outcome of hepatitis B virus-related acute-on-chronic liver failure. World Journal of Gastroenterology, 2014, 20, 2403.	1.4	25
70	Selection of reference genes for RT-qPCR analysis in tumor tissues from male hepatocellular carcinoma patients with hepatitis B infection and cirrhosis. Cancer Biomarkers, 2013, 13, 345-349.	0.8	16
71	Identification of sphingolipids as novel noninvasive biomarkers of liver damage caused by chronic hepatitis B. FASEB Journal, 2013, 27, 815.1.	0.2	1